[{"Assets_0_Q3_USD":606604000.0,"CommonStockSharesOutstanding_0_Q3_shares":101839668.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":76711000.0,"NetIncomeLoss_1_Q3_USD":-12843000.0,"NetIncomeLoss_3_Q3_USD":-49670000.0,"StockholdersEquity_0_Q3_USD":379906000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":23562000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":57615000.0,"Ticker":"SGMO","CIK":"1001233","name":"SANGAMO THERAPEUTICS, INC","OfficialName":"Sangamo Therapeutics Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"750923571.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20181108"}]